Crinetics was founded by scientists dedicated to creating new therapeutics for patients who suffer from endocrine disorders and endocrine-related cancers. Our scientific team has worked together for nearly two decades and has a depth of knowledge and expertise in discovering and developing small molecule drugs that selectively target G-protein coupled receptors (GPCRs).
We opened our laboratories in 2010 and concentrated on building an internal drug discovery pipeline of therapeutics to help endocrinologists and their patients. Our early years were primarily funded by grants. In 2015, Crinetics completed a $40 million Series A venture financing to accelerate development of our pipeline and transition into a clinical-stage company.